Evaluation of [18F]pitavastatin as a positron emission tomography tracer for in vivo organic transporter polypeptide function

被引:6
作者
Yagi, Yusuke [1 ,2 ]
Kimura, Hiroyuki [1 ,2 ]
Okuda, Haruka [1 ]
Ono, Masahiro [1 ]
Nakamoto, Yuji [3 ]
Togashi, Kaori [3 ]
Saji, Hideo [1 ]
机构
[1] Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Pathofunct Bioanal, Sakyo Ku, 46-29 Yoshida Shimoadachi Cho, Kyoto 6068501, Japan
[2] Kyoto Pharmaceut Univ, Dept Analyt & Bioinorgan Chem, Yamashina Ku, 5 Nakauchi Cho, Kyoto 6078414, Japan
[3] Kyoto Univ, Grad Sch Med, Dept Diagnost Imaging & Nucl Med, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan
基金
日本学术振兴会;
关键词
Organic anion transporting polypeptide; Positron-emission tomography; Fluorine-18; Pitavastatin; Integration plot method; HEPATOBILIARY TRANSPORT; HEPATIC ELIMINATION; VITRO; OATP; RATS;
D O I
10.1016/j.nucmedbio.2019.08.001
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Introduction: To understand the pathways involved in drug clearance from the body, quantitative evaluations of the hepatobiliary transport of drugs are important. The organic anion transporting polypeptide (OATP) family transporter, particularly OATP1B1 and 1B3, are considered to play an important role in hepatic uptake of organic anion compounds. Pitavastatin is a substrate of OATP, and it includes a fluorine group. Therefore, it represents an acceptable positron-emission tomography (PET) tracer using fluorine-18 to image in vivo hepatic transporter functions. Method: [F-18]Pitavastatin was synthesized using the method we previously reported. To evaluate the potential of ca n p itavastatin in PET imaging of in vivo OATP functions, we investigated the hepatic uptake with/without rifampicin as an OATP inhibitor after administration in normal SD rats. [F-18]Pitavastatin metabolite was evaluated using reverse-phase thin-layer chromatography (TLC) autoradiography. We subsequently analyzed the PET image results and demonstrated that [F-18]pitavastatin selectively accumulated in the liver post-administration. Result and discussion In metabolite analysis using reverse-phase TLC, we found that the radioactivity detected in the plasma, liver (>90% intact), and bile mostly originated from the parent pitavastatin of the PET study (-40 min). [F-18]pitavastatin's hepatic uptake decreased (approximately 76%) with rifampicin co-administration in PET analysis. Because [F-18]pitavastatin has lower clearance in rats than other previously reported OATP1B PET s, it holds the potential of an imaging tracer that has a higher sensitivity in monitoring hepatic OATP1B function's changes. Conclusion: Compared with the previously reported OATP imaging tracers, [F-18]pitavastatin is more suitable for the sensitive detection of functional changes in OATP transporters. We believe that[F-18]pitavastatin enables quantitative analysis of the hepatobiliary transport system for organic anion compounds. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页码:25 / 31
页数:7
相关论文
共 24 条
  • [1] FUJINO H, 1998, DRUG METAB PHARMACOK, V13, P499, DOI DOI 10.2133/DMPLC13.499
  • [2] PET Imaging of Oatp-Mediated Hepatobiliary Transport of [11C] Rosuvastatin in the Rat
    He, Jiake
    Yu, Yang
    Prasad, Bhagwat
    Link, Jeanne
    Miyaoka, Robert S.
    Chen, Xijing
    Unadkat, Jashvant D.
    [J]. MOLECULAR PHARMACEUTICS, 2014, 11 (08) : 2745 - 2754
  • [3] Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans
    Hirano, M
    Maeda, K
    Shitara, Y
    Sugiyama, Y
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 311 (01) : 139 - 146
  • [4] Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data
    Iwatsubo, T
    Hirota, N
    Ooie, T
    Suzuki, H
    Shimada, N
    Chiba, K
    Ishizaki, T
    Green, CE
    Tyson, CA
    Sugiyama, Y
    [J]. PHARMACOLOGY & THERAPEUTICS, 1997, 73 (02) : 147 - 171
  • [5] A Clinical Quantitative Evaluation of Hepatobiliary Transport of [11C] Dehydropravastatin in Humans Using Positron Emission Tomography
    Kaneko, Ken-Ichi
    Tanaka, Masaaki
    Ishii, Akira
    Katayama, Yumiko
    Nakaoka, Takayoshi
    Irie, Satsuki
    Kawahata, Hideki
    Yamanaga, Takashi
    Wada, Yasuhiro
    Miyake, Takeshi
    Toshimoto, Kota
    Maeda, Kazuya
    Cui, Yilong
    Enomoto, Masaru
    Kawamura, Etsushi
    Kawada, Norifumi
    Kawabe, Joji
    Shiomi, Susumu
    Kusuhara, Hiroyuki
    Sugiyama, Yuichi
    Watanabe, Yasuyoshi
    [J]. DRUG METABOLISM AND DISPOSITION, 2018, 46 (05) : 719 - 728
  • [6] KINETIC-ANALYSIS OF INVIVO RECEPTOR-DEPENDENT BINDING OF HUMAN EPIDERMAL GROWTH-FACTOR BY RAT-TISSUES
    KIM, DC
    SUGIYAMA, Y
    SATOH, H
    FUWA, T
    IGA, T
    HANANO, M
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1988, 77 (03) : 200 - 207
  • [7] Kimata H., 1998, XENOBIO METABOL DISP, V13, P484, DOI [10.2133/dmpk.13.484, DOI 10.2133/DMPK.13.484]
  • [8] Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: Application of in vitro and ex situ systems
    Lau, YY
    Okochi, H
    Huang, Y
    Benet, LZ
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 316 (02) : 762 - 771
  • [9] Maeda K, 2009, HEPATIC TRANSPORT DR, P277, DOI [10.1002/9783527623860.ch11, DOI 10.1002/9783527623860.CH11]
  • [10] The Expression and Function of Organic Anion Transporting Polypeptides in Normal Tissues and in Cancer
    Obaidat, Amanda
    Roth, Megan
    Hagenbuch, Bruno
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 52, 2012, 52 : 135 - 151